Interleukin-2 (IL-2) and interferon-alpha (a-IFN) are cytokines with independent antitumour activities in animal models as well as in some human malignancies including malignant melanoma (MM) and renal cell cancer (RCC). The exact mechanisms by which IL-2 and a-IFN cause tumour regression in vivo are as yet unknown; from experimental studies, however, both agents are known to have a number of functions which possibly contribute to their antitumour efficacy.
IL-2 has initially been described for its capability to support the growth of T lymphocytes. In addition, IL-2 plays a central role in the regulation of cell-mediated non-major histocompatibility complex (MHC)-restricted cytotoxicity.
IL-2 augments the cytolytic activity of natural killer (NK) cells (Henney et al., 1981) and induces the generation of lymphokine-activated killer (LAK) cells (Grimm et al., 1982) . NK cells are lymphocytes exhibiting a spontaneous cytotoxicity against some tumour cells and tumour cell lines (Robertson & Ritz, 1990) . Incubation of peripheral blood lymphocytes (PBL) in IL-2 for at least 3 days results in the generation of LAK cells which are capable of lysing NK resistant tumour cell lines and fresh tumour cells (Grimm et al., 1982) but show only minimal cytotoxicity against normal cells (Sondel et al., 1986) . It has been shown in human and animal studies that significant LAK activity can also be generated in vivo by treatment with appropriate IL-2 regimens.
The cell populations mediating NK and LAK cytotoxicity are functionally defined and composed of phenotypically heterogeneous lymphocyte subpopulations. The surface antigen is expressed by virtually all human NK effectors although they are heterogeneous for the expression of additional markers; moreover, less than 5% of T lymphocytes, monocytes, and neutrophils are Leu-l9+ (Robertson & Ritz, 1990) . is therefore used most extensively as NK cell marker. In addition, expression has been demonstrated in the majority of LAK effectors, and there is considerable evidence that LAK activity is largely mediated by IL-2 activated NK cells (Ortaldo et al., 1986; Weil-Hillman et al., 1989) .
IL-2 also stimulates proliferation of various lymphocyte subpopulations (Bich-Thuy et al., 1986) including NK cells (Trinchieri et al., 1984; Yamada et al., 1987) . After in vivo administration of IL-2, considerable changes in the phenotypic composition of circulating lymphocytes are usually observed, including increased percentages of cells expressing the IL-2 receptor (CD 25) and Lotze et al., 1987 ). a-IFN is known to augment the cytotoxic activity of NK cells (Herberman et al., 1982) . Moreover, a-IFN has direct antiproliferative effects on normal and neoplastic cells (Czarniecki et al., 1984; Fidler et al., 1987) . In tumour cells, a-IFN enhances the expression of cell surface molecules including tumour-associated antigens and class I MHC antigens (Giacomini et al., 1984; Weber & Rosenberg, 1988) and is capable of promoting a partial reversal of the malignant phenotype (Hicks et al., 1981) .
In animal studies, the administration of combined IL-2 and x-IFN resulted in synergistic antitumour efficacy (Brunda et al., 1987; Cameron et al., 1988; Iigo et al., 1989; Kim et al., 1989; Rosenberg et al., 1988) . The mechanisms responsible for this in vivo synergy remain largely speculative, although the interactions between IL-2 and x-IFN have been investigated in a number of in vitro studies. These experimental data clearly show that combination of a-IFN and IL-2 results in a more than additive augmentation of NK activity (Brunda & Davatelis, 1985) . In contrast, in vitro generation of LAK cells seems to be modulated by a-IFN in a complex manner. Culture of PBL in IL-2 and a-IFN may result in either enhanced or impaired LAK activity depending on experimental conditions such as timing of a-IFN addition, sequential or concurrent exposure of PBL to IL-2 and m-IFN, a-IFN concentration, and duration of the culture period (Brunda et al., 1986; Chikkala et al., 1990; Di Raimondo et al., 1987; Sone et al., 1988; Tokuda et al., 1989) . In addition, a-IFN may also affect tumour cells resulting in either increased or reduced susceptibility to NK and LAK cell lysis depending on the experimental conditions and the target cells used (Di Raimondo et al., 1987; Greenberg et al., 1984; Metha et al., 1991; Trinchieri et al., 1981) .
In contrast to an abundance of in vitro studies, only limited data exist on immunological effects of combined IL-2 and a-IFN occurring in vivo. In the present study, we have serially monitored in vivo generated cytotoxicity against K562 and Daudi target cells, lymphocyte proliferation, and expres-patients undergoing treatment with combined IL-2 and a-IFN. Whilst detailed clinical data of this study will be presented elsewhere, we report here on the immunological aspects.
Material and methods

Patients and treatment
The immunological data analysed in this paper were generated by 15 patients entered into a phase II trial. All patients had advanced, progressing MM or RCC. Treatment consisted of concurrent interleukin-2 (IL-2, Proleukin®D; kindly provided by EuroCetus Ltd.*), and interferon-alpha-2a (a-IFN, RoferonO-A; Hoffmann-LaRoche). Both drugs were administered subcutaneously on an outpatient basis. IL-2 was given five times a week (Monday to Friday) in fixed single doses of 18 x 106 IU, and a-IFN was given three times a week (Monday, Wednesday, Friday) in fixed single doses of 3 x 106 IU, for three successive weeks, followed by a rest period of 2 weeks (Figure 1 ). In case of tumour remission or stable disease, treatment was continued to a maximum of four cycles with unchanged drug dosages. All patients included in this analysis received at least one full treatment cycle and were evaluable for clinical response. Complete or partial remissions (CR/PR) were seen in three patients, no change (NC) of tumour parameters in four patients, and progressive disease (PD) in eight patients. All three responders had MM.
Patient monitoring and sample preparation Thirty to forty ml of heparinised blood were drawn from patients on days 1 (pretreatment), 5, 12 and 19 of each treatment cycle (sampling days; see Figure 1 ) for serial assessments of cytotoxicity, surface marker analysis, and proliferation assays. PBL were separated by Ficoll-Hypaque density gradient centrifugation and resuspended in RPMI 1640 tissue culture medium supplemented with L-glutamine (2.0 mM), ampicillin (200 mg 1'), streptomycine (250 mg I') and 10% (v/v) heat-inactivated foetal calf serum (subsequently referred to as 'medium'). Viable cells were then counted by the trypan blue exclusion method. Excess cells were cryopreserved by controlled rate freezing in 10% dimethylsulfoxide and stored in liquid nitrogen.
Cytotoxicity assay
A 4 h 5"Cr-release assay was applied to test cytotoxic activities, using fresh PBL as effector cells and the two tumour cell lines K562 and Daudi as target cells. Details of the technique have been described previously (Ghosh et al., 1989) . Briefly, targets were labelled with 0.1 mCi 51Cr/106 cells for 1 h at 37°C, washed twice, and then incubated for 30 min at 37°C with medium to reduce spontaneous chromium release. After two further washings, the targets were resuspended in medium for a concentration of 5 x 104 cells ml-'. One Tables I and II for each of the 4 E:T ratios tested. An activity of > 10% against the K562 target was observed in 79% of patients before treatment. One patient (who subsequently responded to therapy) had an unusual high pretreatment anti-K562 activity of 74% for the E:T ratio of 100:1, and values up to 46% were found in the remaining patients.
A maximum pretreatment cytotoxicity of 13% against the Daudi target was seen for the same E:T ratio.
Cytotoxicity during the first treatment cycle In vivo induction of cytotoxicity against both K562 and Daudi targets was consistently seen after initiation of IL-2/a-IFN therapy. At an E:T ratio of 100:1, peak anti-K562 activities obtained by individual patients ranged from 28% to 74% (median 50%). Individual peak activities against Daudi targets ranged from 7% to 58% (median 35%), with only one patient not exceeding the 20% limit. The differences between pretreatment and peak activity were statistically significant for both targets at each of the four E:T ratios tested (see Tables I and II) . Figures 2a and 2b show that cytotoxicity was markedly augmented by day 5, the increase since day 1 being statistically significant for both anti-K562 and anti-Daudi activities (P <0.013 for the K562 target, and P<0.009 for the Daudi target, at each of the four E:T ratios; Wilcoxon test). A continuing increase of cytotoxicity levels was seen during the second treatment week before a plateau phase was reached during the third week.
Relationship between cytotoxicity and response Cytotoxicity results were compared between patients grouped according to Tables I and 11 ). The differences between patient groups were statistically significant for the anti-Daudi activity at the E: T ratio of I 00: I but not at the lower ratios, and neither for the anti-K562 activity (Tables I and II) . During the rest period after the first treatment course, responders were able to maintain higher cytotoxicity levels than non-responders. Cytotoxicity duringsubsequent treatment cycles During the second treatment cycle, cytotoxicity levels were again related to the clinical response (Figures 3 and 4) interindividual (on a given sampling day) and intraindividual (during the whole study duration) variabilities. Proliferation of PBL in response to PHA was not associated with clinical response (data not shown).
In vitro stimulation of PBL with IL-2 In pretreatment samples, IL-2 was capable of inducing PBL proliferation in a dose-dependent manner. Median SI for the three IL-2 concentrations tested were 11, 5, and 4, respectively (see Table  IV ). Proliferative responses of PBL to IL-2 temporarily increased during each treatment cycle (see Figure 8) . The results for the first cycle are given in Table IV , and it can be seen that the differences beween pretreatment and peak SI were highly significant (P <0.005 for each of the IL-2 concentrations, Wilcoxon (Ortaldo & Longo, 1988) . In contrast, Daudi cells are LAK-susceptible but relatively NK-resistant targets. It may therefore be concluded that the cytotoxicity induced by IL2/a-IFN treatment is largely due to in vivo generation of LAK activity. Augmented cytotoxicity levels were usually seen after the first five treatment days, but both anti-K562 and anti-Daudi activity continued to increase thereafter, and patients were capable of maintaining elevated cytotoxicity levels throughout the treatment period.
Moreover, levels of anti-K562 and anti-Daudi activity were found to be higher in patients who subsequently responded immunotherapy (Mule et al., 1986) .
Although the number of published therapeutic trials using combined IL-2 and a-IFN is increasing, only few data are reported on monitoring of in vivo cytotoxicity. In vivo induction of cytotoxic activity against NK-and LAK-sensitive targets, but no consistent relationship between antitumour effect and extent of cytotoxicity, has been observed in a phase I trial (Budd et al., 1989) . Others (Pichert et al., 1991) have investigated the inducible cytotoxicity (with additional in vitro stimulation of patients' PBL by IL-2 after IL-2/a-IFN treatment) which must not be mistaken for in vivo cytotoxicity (Lamers et al., 1991) . In one clinical trial, IL-2 has been used in combination with interferon-beta which, like a-IFN, is a type I interferon. Analysis of in vivo cytotoxicity in this study demonstrated a remarkable similarity to our data in so far as maximum killing of NK-and LAK-sensitive target cells was higher in responders than in non-responding patients, the difference being statistically significant for the activity against LAK-sensitive targets (Krigel et al., 1990) .
,In contrast, in vivo generation of cytotoxicity has been monitored in a number of therapeutic studies using IL-2 alone (Creekmore et al., 1989; Gambacorti-Passerini et al., 1988; Ghosh et al., 1989; Klasa et al., 1990; McMannis et al., 1988; Paciucci et al., 1989; Rosenthal et al., 1988; Sosman et al., 1988) . Treatment-induced augmentation of activity against NK-sensitive targets was a common observation. In contrast, in vivo generation of LAK activity was not seen consistently. It appears from these studies that optimum in vivo LAK cell generation requires an IL-2 treatment for at least four consecutive days, corresponding to the in vitro LAK cell generation which requires a minimum duration of 3 days for culture of PBL in IL-2. Moreover, the schedule and route of IL-2 administration is an additional critical factor in obtaining optimum LAK cell activity. For instance, it has become clear that IL-2 given as a continuous intravenous (i.v.) infusion has greater biological effects than the same total dose given as bolus i.v. injection(s) (Kohler et al., 1989; Thompson et al., 1989) . In order to get best in vivo induction of LAK activity, prolonged therapeutic IL-2 serum concentrations may therefore be superior to short though high peak levels. Pharmacokinetic studies suggest that a single IL-2 dose of 18 x 106 IU, as applied in our regimen, given subcutaneously to a typical human with a body surface area of 1.7 m2 will result in a serum level of approximately 100 IU ml-' . This is only 2% of the level which is obtained if the same dose is given as an i.v. bolus, but it is in the same range as the steady state concentration which is obtained after continuous infusion of the same dose over 24 h. Moreover, the serum concentration after a subcutaneous injection remains fairly constant for about 8 h, whereas the serum level after bolus i.v. administration decreases with a half-life of 12.9 min . These data may explain the remarkably high in vivo cytotoxicity levels seen in our study although low to moderate (outpatient) drug dosages have been used. However, our study design was not suitable to assess the relative contribution of a-IFN to the process of cytotoxicity generation.
Most therapeutic studies using IL-2 alone, including one performed in our own institution (Ghosh et al., 1989) , failed to detect any significant differences in in vivo cytotoxicity between responding and non-responding patients. A few trials, however, reported on higher cytotoxicity levels in patients with clinical response (Klasa et al., 1990; Paciucci et al., 1989; Yasumoto et al., 1987) . The variability in these findings suggests that many factors related both to the treatment and to the cytotoxicity assay (frequency and timing of assays, expression of cytolytic activity as percentage cytotoxicity or as lytic units, target cells and E:T ratios used) may be crucial for detection of a significant correlation between cytotoxicity levels and clinical outcome.
Leu-19 is a surface marker which is expressed by a minority of normal PBL, and Leu-19+ cells typically mediate NK cytotoxicity . There is some evidence that LAK cells generated in vivo are largely confined to the Leu-19+ cell population although they are heterogeneous for co-expression of additional markers McMannis et al., 1988; Weil-Hillman et al., 1989) . In the present study we were able to demonstrate a statistically significant increase in the relative number of Leu-19+ cells during IL-2/a-IFN treatment. This result is in agreement with findings in other clinical studies using IL-2 in combination with a-IFN (Budd et al., 1990; Pichert et al., 1991; Zinzani et al., 1990) or alone (Creekmore et al., 1989; Klasa et al., 1990; Sosman et al., 1988) . The proportion of Leu-19+ cells increased throughout the first treatment cyclie, the peak percengage being reached at the end of the 3 week treatment period. A continuing expansion of Leu-19+ lymphocytes during the whole treatment period was also observed in a study where patients were treated with IL-2 alone for 4 weeks .
The CD 25 molecule (Tac antigen), which is expressed by activated lymphocytes and monocytes, is known to function as low affinity receptor for IL-2. There is clear evidence from in vitro studies that the proportion of CD 25+ cells increases after incubation of PBL with IL-2, but this process is partially inhibited when additional a-IFN is present in the cultures (Di Raimondo et al., 1987; Sone et al., 1988; Tokuda et al., 1989) . Increased percentages of CD 25+ lymphocytes have also been observed after in vivo treatment with IL-2 for several consecutive days (Gambacorti-Passerini et al., 1988; Ghosh et al., 1989; Klasa et al., 1990; Sondel et al., 1988; Sosman et al., 1988) whilst regimens using a single weekly IL-2 dose had little if any effect (Atkins et al., 1986; Creekmore et al., 1989; Thompson et al., 1987) . In our study the relative number of CD 25+ peripheral lymphocytes was found to increase significantly after initiation of treatment for a peak on day 12, followed by a plateau phase through to day 19, thus indicating that maximum cell activation was achieved after the second treatment week. The similar kinetics of CD 25+ expression and cytotoxic activity during the first treatment cycle is noteworthy.
Interestingly the phenotype analysis in our study revealed that peak percentages of Leu-19+ PBL were higher in responding patients than in patients with progressing disease. In contrast, peak percentages of CD 25+ cells were lower in responders than in non-responders. These results are remarkably consistent with data recently reported by another group (Kirchner et al., 1990; Lopez Hanninen et al., 1991) . In their study, the same correlations between clinical response and expression of by peripheral blood cells were observed in cancer patients who were, as in our study, treated with concomitant subcutaneous IL-2 and a-IFN for a prolonged period.
A prominent effect of IL-2 is the induction of PBL proliferation (Bich-Thuy et al., 1986) . In contrast, a-IFN has antiproliferative properties, and proliferation of human PBL (as well as murine spleen cells) is inhibited after co-incubation with IL-2 and a-IFN as compared to culture in IL-2 alone (Brunda et al., 1986; Di Raimondo et al., 1987; Sone et al., 1988; Tokuda et al., 1989 ). In our study, patients' PBL obtained repeatedly during in vivo treatment were tested for their ability to proliferate in vitro by incubation in medium alone, i.e. without further in vitro drug exposure. This spontaneous PBL proliferation was clearly inhibited by the in vivo treatment, a result which is in agreement with the in vitro data mentioned. In contrast, augmented spontaneous PBL proliferation was observed after in vivo treatment with IL-2 alone (Gambacorti-Passerini et al., 1988) . It is therefore most likely that the inhibition of PBL proliferation in our study was due to the antiproliferative effect of x-IFN. This conclusion is supported by the observation that spontaneous PBL proliferation recovered during the treatment free intervals.
There is some evidence that generation of LAK cytotoxicity results from a functional activation rather than from a proliferative expansion of LAK precursors (Blay et al., 1989; Ramsdell et al., 1988) . Moreover, kinetic studies revealed that IL-2 induced enhancement of NK cytotoxicity in PBL preceded any proliferation (Trinchieri et al., 1984) . Therefore induction of cytotoxic activity and lymphocyte proliferation seem to be two largely independent processes following IL-2 exposure which do not necessarily need to be concordant, and the relatively high cytotoxicity levels observed in our study are not in contradiction to the inhibition of PBL proliferation.
We have also serially examined the proliferative responses of patients' PBL to in vitro stimulation with IL-2 and PHA. Augmented PBL proliferation in the presence of IL-2 in vitro was consistently seen during all four in vivo treatment cycles. This finding indicates that the in vivo treatment resulted in activation of a PBL subpopulation which was capable of responding with more rapid kinetics to IL-2 in vitro. Similar results were seen in patients who have been treated with IL-2 alone over several consecutive days (Rosenthal et al., 1988; Sosman et al., 1988) . In contrast, PBL proliferation in response to PHA, a T cell mitogen, did not appear to change reproducibly during treatment, and the variability between individual patients was high. Comparable observations were reported when patients' PBL were stimulated with PHA in vitro after in vivo treatment with IL-2 alone (Paciucci et al., 1989; Rosenthal et al., 1988; Sosman et al., 1988; Thompson et al., 1987) .
In conclusion, remarkable imnmunomodulatory effects were seen in the present study. Our data have been generated by a relatively small number of patients and need to be confirmed in larger patient series. The significant correlation between in vivo cytotoxicity against Daudi targets and response to therapy is of special clinical interest, since immune parameters correlating with subsequent clinical outcome in the early phase of immunotherapy might be helpful in selecting patients who are likely to respond to prolonged treatment. This issue should be addressed by future studies.
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